4//SEC Filing
Feltquate David 4
Accession 0000950170-25-112238
CIK 0001808865other
Filed
Aug 28, 8:00 PM ET
Accepted
Aug 29, 4:30 PM ET
Size
7.1 KB
Accession
0000950170-25-112238
Insider Transaction Report
Form 4
Feltquate David
Chief Medical Officer
Transactions
- Disposition from Tender
Common Stock
2025-08-29−47,000→ 0 total
Footnotes (3)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company and thereafter, the Merger Sub merged with and into the Company (the "Merger"). The amount reported in Column 4 includes 47,000 restricted stock units of the Company ("Company Restricted Stock Units," and each such restricted stock unit, a "Company Restricted Stock Unit").
- [F2](Continued from footnote 1) Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, (A) each Company Restricted Stock Unit that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company (each such Company Restricted Stock Unit, an "Accelerated Vesting Restricted Stock Unit")
- [F3](Continued from footnote 2) that was then outstanding but not then vested became immediately vested in full and (B) each Accelerated Vesting Restricted Stock Unit that was then outstanding was canceled and, in exchange therefor, the holder of such canceled Company Restricted Stock Unit became entitled to receive in consideration of the cancellation of such Company Restricted Stock Unit (x) an amount in cash without interest, subject to any applicable tax withholding, equal to $10.047 in cash per share and (y) one non-transferable contractual contingent value right per share.
Documents
Issuer
iTeos Therapeutics, Inc.
CIK 0001808865
Entity typeother
Related Parties
1- filerCIK 0002031518
Filing Metadata
- Form type
- 4
- Filed
- Aug 28, 8:00 PM ET
- Accepted
- Aug 29, 4:30 PM ET
- Size
- 7.1 KB